Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page

New European guidelines set to benefit heart failure patients in the UK

Thursday, 07 Jun 2012 11:13

The new guidelines state that the combination of “an ACE inhibitor [or angiotensin receptor blocker (ARB)], a beta-blocker, and an MRA, are fundamentally important in modifying the course of systolic heart failure and should at least be considered in every patient”.


This update provides welcome guidance to UK clinicians as it builds upon existing NICE guidance developed before the EMPHASIS-HF trial results were published.


Results of the EMPHASIS-HF trial showed that eplerenone (Inspra, Pfizer) reduces the risk of cardiovascular death or heart failure hospitalisation by more than a third compared to placebo in heart failure patients already receiving current standard therapy (RRR = 37%, p<0.001; ARR = 7.6%, p<0.001). These results were achieved against a quality of background therapy seldom seen in day to day clinical practice – 94% of patients in the eplerenone arm were also receiving an ACE inhibitor and over 86% were receiving a beta-blocker – highlighting the additive benefit of MRAs over standard therapy.


“The inclusion of eplerenone and mineralocorticoid receptor antagonists in the latest ESC guidelines is a significant step in making these life saving and cost effective treatments available to patients that need them,” said Martin Cowie, professor of Cardiology at Imperial College and consultant cardiologist at the Royal Brompton Hospital, London, UK. “Eplerenone should be offered to all eligible patients who continue to exhibit symptoms as it has been shown not only to save lives but, importantly, help keep patients out of hospital.”


Eplerenone has also been shown to reduce the likelihood of patients being admitted to hospital (due to heart failure) by over 40% (RRR 42%, p<0.001; ARR 6.8%, p<0.001). Hospitalisation due to HF is commonplace and every heart failure emergency admission costs at least £2,400.


Health economic analysis of eplerenone in patients with chronic heart failure (NYHA class II) have shown that eplerenone as an add-on to standard optimal therapy is highly cost-effective compared to standard therapy alone, with an incremental cost per Quality Adjusted Life Year (QALY) gained of £3,534, well below the lower £20,000 threshold typically viewed by NICE as representing good value for money.


Eplerenone has recently been approved in the UK to reduce the risk of cardiovascular mortality and morbidity in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (left ventricular ejection fraction ≤30%), in addition to standard optimal therapy. It is also indicated to treat patients with heart failure and left ventricular ejection fraction ≤ 40%, after recent myocardial infarction again, alongside standard therapy.

Add New Comment

Most popular

Long-term results of RESPECT indicate that PFO closure may be effective at preventing recurrent stroke
Friday, 16 Oct 2015
The long-term study results from the RESPECT trial found that closing a patent foramen ovale (PFO) with an Amplatzer PFO Occluder was superior to medical management in the prevention of recurrent ... Long-term results of RESPECT indicate that PFO closure may be effective at preventing recurrent stroke

Custom-designed vascular training model now available at events
Thursday, 05 Nov 2015
The ThinkRadial Vascular Training Model provides realistic simulation to several procedurally critical vascular destinations, while allowing the practitioner to “see” the way radial products perform ... Custom-designed vascular training model now available at events

Friday, 16 Oct 2015
Edwards Lifesciences has announced a one-year survival rate of 89.3% for high-risk patients who received the Edwards Sapien 3 transcatheter aortic valve via transfemoral, as well as low rates of ... Edwards Sapien 3 valve demonstrates high survival and low stroke rate at one year


An interventional cardiologist’s view on left atrial appendage closure
Thursday, 12 Nov 2015
Martin W Bergmann is an interventional cardiologist working in Germany, who performs percutaneous LAA closure procedures. He explores why there is still a need for such procedures even in the era of ... An interventional cardiologist’s view on left atrial appendage closure

The risk of stroke in patients undergoing TAVI
Friday, 30 Oct 2015
While TAVI is the standard of care for inoperable patients with severe symptomatic aortic stenosis and a compelling approved alternative to surgical aortic valve replacement for patients at high ... The risk of stroke in patients undergoing TAVI


Corrado Tamburino
Tuesday, 20 Oct 2015
Corrado Tamburino (full professor of Cardiology, Ferrarotto & Policlinico Hospitals, University of C... Corrado Tamburino

Javier Escaned
Wednesday, 02 Sep 2015
Javier Escaned (head of Section, Interventional Cardiology Unit, Hospital Clinico San Carlos, M... Javier Escaned

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions